Anti-African horse pestivirus VP7 protein murine recombinant antibody and preparation method thereof

By screening and applying monoclonal antibodies against the VP7 protein of African horse plague virus, a competitive ELISA detection method was established, which solved the problem of insufficient sensitivity and specificity of existing detection methods, and achieved a more efficient detection effect of African horse plague virus.

CN119039428AActive Publication Date: 2024-11-29LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411156911.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-29
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The existing African horse plague virus detection methods have problems with insufficient sensitivity and specificity, especially in large-scale sample detection and epidemiological investigations, which are difficult to effectively identify virus population-specific antibodies.

Method used

Monoclonal antibodies against the African horse plague virus VP7 protein and their heavy and light chain variable region sequences were screened, and competitive ELISA detection methods were used to identify the recombinant VP7 protein and BHK21 expressed by E. coli through murine recombinant antibodies. The recombinant VP7 protein expressed in cells reacts specifically.

Benefits of technology

It has achieved higher sensitivity and specificity, and is suitable for the detection and diagnosis of African horse plague virus, and has better detection effects than existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039428A_ABST
    Figure CN119039428A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a mouse recombinant antibody for resisting African horse pestivirus VP7 protein and a preparation method of the mouse recombinant antibody. The method comprises the following steps: screening a hybridoma cell strain 2B8 aiming at African horse pestivirus VP7 protein by using a hybridoma cell technology, splitting the hybridoma cell strain 2B8 by using Trizol, extracting total RNA (Ribonucleic Acid), and amplifying by using a nested PCR (Polymerase Chain Reaction) method to obtain heavy chain and light chain variable region sequences; the heavy chain and light chain variable region sequences are constructed on a vector containing a murine source constant region, and the recombinant antibody for resisting the African horse pestivirus VP7 protein is successfully expressed and obtained; the recombinant antibody can recognize recombinant VP7 protein expressed by escherichia coli and is subjected to specific reaction with the recombinant VP7 protein expressed in a BHK21 cell; the recombinant antibody can be used for establishing an African horse pestivirus competitive ELISA antibody detection method, and a technical basis is provided for effectively preventing and controlling African horse pestivirus from entering China.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of in vitro diagnosis, and in particular relates to a mouse-derived recombinant antibody against VP7 protein of African horse sickness virus and a preparation method thereof. Background Art

[0002] African horse sickness is a non-contact acute or subacute infectious disease of horses, donkeys, mules and other equine animals caused by the African horse sickness virus (AHSV). The African horse sickness virus belongs to the genus Orbivirus of the family Reoviridae. Its genome consists of 10 double-stranded RNA fragments of different sizes, encoding a total of 7 structural proteins (VP1-VP7) and 4 non-structural proteins (NS1-NS4). Among them, VP2 is a serotype-specific antigen used to distinguish the serotypes of African horse sickness virus, while the VP7 protein is a serogroup-specific antigen and can be used to establish a diagnostic method for African horse sickness virus. Current studies have shown that there are 9 serotypes of African horse sickness virus. The ELISA diagnostic method based on the VP7 protein can be used to detect group-specific antibodies of African horse sickness virus for large-scale sample detection and epidemiological surveys.

[0003] At present, the methods for detecting African horse sickness virus include enzyme-linked immunosorbent assay, virus neutralization test, real-time fluorescence quantitative PCR, RT-PCR based on agarose gel electrophoresis, etc. At present, the competitive ELISA method is commonly used, but the competitive antibody is the key component of the kit. The present invention screens and obtains a monoclonal antibody against AHSV VP7 protein and its heavy chain and light chain variable region sequences, and uses the antibody as a competitive antibody to establish an AHSV competitive ELISA antibody detection method. Summary of the invention

[0004] In response to the above technical problems, the present invention provides a mouse-derived recombinant antibody against the VP7 protein of African horse sickness virus and a preparation method thereof. The mouse-derived recombinant antibody has the characteristics of high titer, strong affinity and good specificity, and can recognize the recombinant VP7 protein expressed in Escherichia coli and specifically react with the recombinant VP7 protein expressed in BHK21 cells.

[0005] Specifically include the following:

[0006] In a first aspect, the present invention provides a recombinant antibody against African horse sickness virus VP7 protein, wherein the recombinant antibody comprises an antibody heavy chain and an antibody light chain;

[0007] The variable region CDR of the antibody heavy chain includes CDR1 with an amino acid sequence as shown in SEQ ID NO.5, CDR2 with an amino acid sequence as shown in SEQ ID NO.6, and CDR3 with an amino acid sequence as shown in SEQ ID NO.7;

[0008] The variable region CDR of the antibody light chain includes CDR1 with an amino acid sequence as shown in SEQ ID NO.8, CDR2 with an amino acid sequence as shown in SEQ ID NO.9, and CDR3 with an amino acid sequence as shown in SEQ ID NO.10.

[0009] Preferably, the amino acid sequence of the variable region of the antibody heavy chain is shown as SEQ ID NO.1, and the amino acid sequence of the variable region of the antibody light chain is shown as SEQ ID NO.3.

[0010] In a second aspect, the present invention provides a nucleic acid encoding the antibody heavy chain and antibody light chain of the recombinant antibody described in the first aspect above.

[0011] Preferably, the gene sequence encoding the variable region of the antibody heavy chain is shown as SEQ ID NO.2, and the gene sequence encoding the variable region of the antibody light chain is shown as SEQ ID NO.4.

[0012] In a third aspect, the present invention provides the use of the recombinant antibody described in the first aspect in the in vitro detection of African horse sickness virus for non-disease diagnosis purposes.

[0013] In a fourth aspect, the present invention provides the use of the recombinant antibody described in the first aspect above in the preparation of a reagent, a test strip, or a kit for detecting African horse sickness virus.

[0014] In a fifth aspect, the present invention provides an African horse sickness virus ELISA detection kit, the kit comprising the recombinant antibody described in the first aspect above.

[0015] Preferably, the kit comprises an ELISA plate, an African horse sickness virus antigen, a blocking solution, a diluent, the recombinant antibody described in the first aspect, an enzyme-labeled secondary antibody, a washing solution, a color developer, and a stop solution.

[0016] Preferably, the blocking solution is PBST buffer containing 5% skimmed milk powder.

[0017] Preferably, the diluent is 0.01M PBS pH 7.2.

[0018] Preferably, the washing solution is PBST buffer.

[0019] Preferably, the enzyme-labeled secondary antibody is a goat anti-mouse secondary antibody labeled with HRP.

[0020] Preferably, the African horse sickness virus antigen is selected from the African horse sickness virus VP7 recombinant protein.

[0021] In a sixth aspect, the present invention provides a method for preparing the recombinant antibody according to the first aspect, the method comprising the following steps:

[0022] (1) amplifying the light chain variable region sequence and the heavy chain variable region sequence encoding the recombinant antibody described in the first aspect, and constructing them into vectors containing mouse constant regions, respectively, to obtain the light chain expression plasmid and the heavy chain expression plasmid of the recombinant antibody;

[0023] (2) The light chain expression plasmid and the heavy chain expression plasmid were transfected into 293F suspension cells at a ratio of 1:1, and the recombinant antibody was obtained by culture and purification.

[0024] The beneficial effects of the present invention are as follows: ① the present invention screens a hybridoma cell line 2B8 targeting the VP7 protein of the African horse sickness virus using hybridoma cell technology, and the hybridoma cell line 2B8 is lysed with Trizol to extract total RNA, and the heavy chain and light chain variable region sequences encoding the antibody are amplified using a nested PCR method; and the heavy chain and light chain variable region sequences are constructed into a vector containing a mouse constant region, and a mouse recombinant antibody targeting the VP7 protein of the African horse sickness virus is successfully expressed; ② the mouse recombinant antibody can recognize the recombinant VP7 protein expressed by Escherichia coli and specifically react with the recombinant VP7 protein expressed in BHK21 cells, and can be used for the detection and diagnosis of the African horse sickness virus; ③ the mouse recombinant antibody can be used to establish a competitive ELISA antibody detection method for the African horse sickness virus. Compared with the existing antibody detection method, the method has better sensitivity and specificity, and is suitable for the detection and diagnosis of the African horse sickness virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 PCR amplification results of the light and heavy chains of the recombinant antibody 2B8;

[0026] Figure 2 SDS-PAGE verification results of recombinant antibody 2B8;

[0027] Figure 3 WB results of recombinant antibody 2B8 and VP7 protein of African horse sickness virus;

[0028] Figure 4 IFA results of recombinant antibody 2B8 and African horse sickness virus VP7 protein. DETAILED DESCRIPTION

[0029] The embodiments of the present invention are described in detail below. It should be noted that the embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. In addition, if not explicitly stated, all reagents used in the following embodiments are commercially available, or can be synthesized according to text or known methods, and the reaction conditions not listed are easily available to those skilled in the art.

[0030] Example 1 Preparation of recombinant antibody 2B8 against African horse sickness virus VP7 protein

[0031] The hybridoma cell line 2B8 targeting the VP7 protein of African horse sickness virus was screened by hybridoma cell technology; the hybridoma cell line 2B8 cells were lysed with Trizol and the total RNA was extracted, and then the cDNA was obtained using a reverse transcription kit. The obtained cDNA template was used to amplify the light chain and heavy chain variable region sequences using the nested PCR method, and then verified by agarose gel electrophoresis. The PCR amplification results of the light chain and heavy chain of the recombinant antibody 2B8 are shown in Figure 2. Figure 1 shown.

[0032] After the amplified product was recovered from the gel, it was connected to the pMD20-T vector using a TA cloning kit and then sent for sequencing. The sequencing results were analyzed using IMGT to obtain the light chain and heavy chain variable region sequences of the recombinant antibody 2B8. The details are as follows:

[0033] The amino acid sequence of the heavy chain variable region of the recombinant antibody 2B8: EVLLQQSGPELVKPGAPVKISCKASGYTFADY NMGWVKQSHGKGLEWIGDINPNNGEIIFIQKLRGRATLTVDKSSSTAYMELRGLTSEDTAVYYCARRGFNDGGDYFDYWGQGTTLTVSS (shown in SEQ ID NO.1);

[0034] Gene sequence encoding the heavy chain variable region of recombinant antibody 2B8: GAGGTCCTGCTGCAACAGTCTGGACCTG AGCTGGTGAAGCCTGGGGCTCCAGTGAAGATATCCTGCAAGGCTTCTGGATACACATTCGCTGACTACAACATGGGCTGGGTGAAGCAGAGCCATGGAAAGGGCCTTGAGTGGATTGGAGATATTAATCCTAACAATGGTGAAATTATTTTCATCCAGAAACTGAGGGG CAGGGCCACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAACTCCGCGGCCTGACATCTGAGGACACTGCAGTCTATTACTGTGCAAGGAGGGGGTTCAATGATGTGGTGACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA(SEQ ID NO.2 shown);

[0035] Wherein, CDR1: GYTFADYN (shown in SEQ ID NO.5);

[0036] CDR2: INPNNGEI (shown in SEQ ID NO. 6);

[0037] CDR3: ARRGFNDGGDYFDY (shown in SEQ ID NO. 7);

[0038] The amino acid sequence of the light chain variable region of the recombinant antibody 2B8 is as follows: DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSN GNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSSHVPLTFGAGTKLELKR (shown in SEQ ID NO.3);

[0039] The gene sequence encoding the light chain variable region of the recombinant antibody 2B8: GATGTTTTGATGACCCAAACTCCACTCTC CCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTGTACATAGTAATGGAAACACCTATTTAGAATGGTACCTACAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAAGTTCACATGTTCCGCTCACGTTCGGTGCTGGGACCAAACTGGAGCTGAAACGG (shown in SEQ ID NO.4);

[0040] Among them, CDR1: QSIVHSNGNTY (shown in SEQ ID NO.8);

[0041] CDR2: KVS (shown in SEQ ID NO. 9);

[0042] CDR3: FQSSHVPLT (shown in SEQ ID NO. 10).

[0043] The light chain variable region sequence and the heavy chain variable region sequence encoding the recombinant antibody 2B8 were respectively constructed onto vectors containing mouse constant regions to form a light chain recombinant vector PTT5-LV-2B8 and a heavy chain recombinant vector PTT5-HV-2B8.

[0044] One day before transfection, adjust the cell density of 293F cells to 1×10 6 cells / mL, and cultured until the next day when the cell density reached 2×10 6 cells / mL. Mix the recombinant vector PTT5-LV-2B8 and PTT5-HV-2B8 in a ratio of 1:1, and then mix with the transfection reagent in a ratio of 1:3 and incubate at room temperature for 10-15 minutes. Then slowly add it to the 293F suspension cells and culture them at 37°C, 8% CO2 and 125rpm for 7 days.

[0045] The cell supernatant after 7 days of culture was collected, filtered and added to the Protein A column pre-equilibrated with Binding / Wash Buffer (0.15MN aCl, 20mM Na2HPO4, pH 7.0), the flow rate was controlled at 2ml / min, and then 10 column volumes of Binding / Wash Buffer were used to wash. The antibody was then eluted with 4 column volumes of Elution Buffer (0.1Mglyci ne, pH 3.0), and 1 / 10 volume of Neutralization Buffer (1M T ris-HCl, pH 8.5) was added to the collected antibody. The antibody was drawn into a 10kDa ultrafiltration tube for concentration, and finally the concentrated mouse recombinant antibody 2B8 was obtained. The purified antibody was analyzed for purity and molecular weight using SDS-PAGE.

[0046] SDS-PAGE verification results are as follows Figure 2 As shown, it was demonstrated that the mouse recombinant antibody 2B8 was successfully expressed and purified.

[0047] Example 2 Reactivity of mouse recombinant antibody 2B8 with African horse sickness virus VP7 protein

[0048] The function of mouse recombinant antibody 2B8 was verified by WB, ELISA and IFA.

[0049] Immunoblotting detection of mouse recombinant antibody 2B8: The expressed AHSV VP7 recombinant protein was used to prepare the sample for immunoblotting. The primary antibody was the mouse recombinant antibody 2B8 (1:1000) prepared in Example 1. The samples were incubated at room temperature for 1 hour, washed 3 times with PBST, each for 10 minutes. The secondary antibody was HRP-labeled goat anti-mouse IgG (1:10000), incubated at room temperature for 1 hour, washed 3 times with PBST, and finally observed by color development.

[0050] WB results are as follows Figure 3 As shown, it is demonstrated that the mouse recombinant antibody 2B8 prepared in the present application is able to recognize the recombinant VP7 protein of African horse sickness virus.

[0051] Indirect ELISA detection of mouse recombinant antibody 2B8: AHSV VP7 recombinant protein was diluted to 0.5 μg / mL and 100 μL / well with CBS buffer (0.05M carbonate-bicarbonate buffer, pH9.6) and coated on the ELISA plate at 4°C overnight. Wash the plate 5 times with PBST buffer. Block the ELISA plate with PBST buffer containing 5% skim milk powder, 200 μL / well, and incubate at 37°C for 1h. Wash the plate 5 times with PBST buffer. The mouse recombinant antibody 2B8 prepared in Example 1 was diluted 1:1000, 100 μL / well, and added to the ELISA plate. A negative control was set at the same time, incubated at 37°C for 1h, and the plate was washed 5 times with PBST buffer. HRP-labeled goat anti-mouse secondary antibody diluted 1:40000 (diluent is 0.01M PBS pH7.2) was added to the ELISA plate, 100 μL / well, and incubated at 37°C for 1h. Wash the plate 5 times with PBST buffer. Develop with TMB colorimetric solution in the dark, 100 μL / well, incubate at 37°C for 10 min; add stop solution 100 μL / well, and read OD 450 The value of .

[0052] The indirect ELISA results are shown in Table 1, indicating that the mouse recombinant antibody 2B8 described in the present application can react with the recombinant VP7 protein of African horse sickness virus.

[0053] Table 1 Indirect ELISA results of mouse recombinant antibody 2B8

[0054] 2B8 Negative control <![CDATA[OD 450 Value]]> 3.7095 / 3.7003 0.1399 / 0.1167

[0055] IFA detection of mouse recombinant antibody 2B8: The mouse recombinant antibody 2B8 prepared in Example 1 was used to perform immunofluorescence analysis on BHK21 cells transfected with a recombinant plasmid expressing AHSV VP7 protein (pcDNA3.1-AHSVVP7, which can be prepared by conventional means). Specifically, BHK21 cells were plated, and the recombinant plasmid pcDNA3.1-AHSVVP7 was transfected into BHK21 cells using Lipofectamine 3000, cultured at 37°C for 24 hours, the cell culture supernatant was discarded, fixed with 4% paraformaldehyde for 10 minutes, washed 3 times with PBS, and then treated with 0.5% Triton X-100 for 10 minutes, washed 3 times with PBS, and blocked with 3% BSA for 1 hour. After absorbing and discarding the old solution, the recombinant antibody 2B8 prepared in Example 1 (1:1000) was added, and mouse negative serum was used as a negative control. After overnight incubation at 4°C, the cell nuclei were stained with Hoechst 33342 for 10 min, washed three times with PBS, and goat anti-mouse IgG (Alexa Fluor 488) were incubated at room temperature in the dark for 1 h, and the slides were sealed and observed and images were collected.

[0056] IFA results are as follows Figure 4As shown, it is demonstrated that the mouse recombinant antibody 2B8 described in the present application is capable of recognizing the recombinant VP7 protein of African horse sickness virus.

[0057] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A recombinant antibody against VP7 protein of African horse sickness virus, It is characterized in that The recombinant antibody comprises an antibody heavy chain and an antibody light chain; The variable region CDR of the antibody heavy chain includes CDR1 with an amino acid sequence as shown in SEQ ID NO.5, CDR2 with an amino acid sequence as shown in SEQ ID NO.6, and CDR3 with an amino acid sequence as shown in SEQ ID NO.7; The variable region CDR of the antibody light chain includes CDR1 with an amino acid sequence as shown in SEQ ID NO.8, CDR2 with an amino acid sequence as shown in SEQ ID NO.9, and CDR3 with an amino acid sequence as shown in SEQ ID NO.

10.

2. The recombinant antibody according to claim 1, It is characterized in that The amino acid sequence of the variable region of the antibody heavy chain is shown in SEQ ID NO.1, and the amino acid sequence of the variable region of the antibody light chain is shown in SEQ ID NO.

3.

3. a nucleic acid, It is characterized in that The nucleic acid encodes the antibody heavy chain and antibody light chain of the recombinant antibody according to claim 1 or 2.

4. The nucleic acid according to claim 3, It is characterized in that The gene sequence encoding the variable region of the antibody heavy chain is shown in SEQ ID NO.2, and the gene sequence encoding the variable region of the antibody light chain is shown in SEQ ID NO.

4.

5. Use of the recombinant antibody as claimed in claim 1 or 2 in in vitro detection of African horse sickness virus for non-disease diagnosis purposes.

6. Use of the recombinant antibody as claimed in claim 1 or 2 in the preparation of a reagent, test strip or kit for detecting African horse sickness virus.

7. An ELISA test kit for African horse sickness virus, It is characterized in that The kit comprises the recombinant antibody according to claim 1 or 2.

8. The ELISA test kit according to claim 7, It is characterized in that The kit comprises an ELISA plate, an African horse sickness virus antigen, a blocking solution, a diluent, the recombinant antibody according to claim 1 or 2, an enzyme-labeled secondary antibody, a washing solution, a color developer, and a stop solution.

9. The ELISA detection kit according to claim 7 or 8, It is characterized in that The African horse sickness virus antigen is selected from the African horse sickness virus VP7 recombinant protein.

10. The method for preparing a recombinant antibody according to claim 1 or 2, It is characterized in that The method comprises the following steps: (1) amplifying the light chain variable region sequence and the heavy chain variable region sequence encoding the recombinant antibody of claim 1 or 2, and constructing them into vectors containing mouse constant regions, respectively, to obtain the light chain expression plasmid and the heavy chain expression plasmid of the recombinant antibody; (2) The light chain expression plasmid and the heavy chain expression plasmid were transfected into 293F suspension cells at a ratio of 1:1, and the recombinant antibody was obtained by culture and purification.

Citation Information

Patent Citations

  • Kit for detecting African horse pestivirus and application thereof

    CN116041447A

  • Monoclonal antibody aiming at African horse pestivirus VP7 protein and application thereof

    CN116769021A

  • Monoclonal antibody with good affinity reaction capacity with African horse pestivirus VP7 protein and application

    CN117700537A